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S U M M A R Y
Background: In November 2010, following reports of an outbreak of a fatal, febrile, hemorrhagic illness in
northern Uganda, the Uganda Ministry of Health established multisector teams to respond to the
outbreak.
Methods: This was a case-series investigation in which the response teams conducted epidemiological
and laboratory investigations on suspect cases. The cases identiﬁed were line-listed and a data analysis
was undertaken regularly to guide the outbreak response.
Results: Overall, 181 cases met the yellow fever (YF) suspected case deﬁnition; there were 45 deaths
(case fatality rate 24.9%). Only 13 (7.5%) of the suspected YF cases were laboratory conﬁrmed, and
molecular sequencing revealed 92% homology to the YF virus strain Couma (Ethiopia), East African
genotype. Suspected YF cases had fever (100%) and unexplained bleeding (97.8%), but jaundice was rare
(11.6%). The overall attack rate was 13 cases/100 000 population, and the attack rate was higher for
males than females and increased with age. The index clusters were linked to economic activities
undertaken by males around forests.
Conclusions: This was the largest YF outbreak ever reported in Uganda. The wide geographical case
dispersion as well as the male and older age preponderance suggests transmission during the outbreak
was largely sylvatic and related to occupational activities around forests.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Yellow fever (YF) is an acute viral hemorrhagic disease caused
by the yellow fever virus. The YF virus is an enveloped positive
sense single-stranded RNA virus that belongs to the genus
Flavivirus.1 The natural host of the virus is non-human primates
and the vectors in Africa are usually mosquitoes of species Aedes
africanus in forest areas and Aedes aegypti in urban areas.2
In humans, the acute phase occurs 3–6 days after infection and
is characterized by non-speciﬁc symptoms that last up to 4 days.
Fifteen percent of the patients enter a toxic phase characterized by* Corresponding author. Tel.: +256 772 481229.
E-mail address: j_wamala@yahoo.com (J.F. Wamala).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.03.004high fever, unexplained bleeding, jaundice, and multiple organ
failure, and 50% of these patients die within 2 weeks.3
To conﬁrm the disease, serological testing by way of ELISA for YF
virus-speciﬁc IgM or isolation of the virus from blood samples is
usually undertaken, since these are the recommended standard
diagnostic tests for YF.4 Blood samples may be subjected to PCR
testing or exceptionally to next generation sequencing (NGS)5 for
the detection of YF virus genetic material. Immunohistochemical
techniques are valuable for detecting the viral antigen in liver
autopsy tissues.4 Treatment is supportive since there is no known
cure,6 and vaccination is the mainstay of YF control.7
YF is a moving epizootic in endemic regions of tropical Africa
and South America lying within a band from 158N to 108S of the
equator and accounts for an estimated 200 000 cases of YF (with
30 000 deaths) per year globally.8ses. Published by Elsevier Ltd. All rights reserved.
J.F. Wamala et al. / International Journal of Infectious Diseases 16 (2012) e536–e542 e537The largest YF outbreak in East Africa occurred in Ethiopia from
1960 to 1962 and accounted for about 30 000 deaths.9 YF
outbreaks have also been reported from Sudan (1940,10 2003,11
and 200512) and Kenya (1992–9313). The ﬁrst YF outbreak in
Uganda was reported in 1941 from Bwamba County, western
Uganda.14 Subsequent YF outbreaks in Uganda were reported in
Kabarole District in 1952,15 Entebbe in 1959 and 1971,16 and
Luwero in 1964.17
After 1972, political instability in the country led to a decline in
YF surveillance activities in Uganda and hence many suspected YF
cases notiﬁed by the health facilities were not investigated.
Following the introduction of the Integrated Disease Surveillance
and Response (IDSR) strategy in Uganda in 2000,18 a clinical health
facility-based surveillance system for YF was instituted, though
most of these reports were not accompanied by specimens to
facilitate laboratory investigations. It is therefore possible that
undetected human cases were occurring despite the absence of
conﬁrmed outbreaks in the country over the past four decades.
In November 2010, the Uganda Ministry of Health received
reports of an outbreak of a fatal, febrile, hemorrhagic illness in
northern Uganda. Multisector teams were established to support
the outbreak response. This report highlights the activities and
ﬁndings of the epidemiology and laboratory team during the
outbreak. Entomological and reactive vaccination outcomes will be
reported separately.
2. Methods
2.1. Epidemic site
A total of 15 districts in northern Uganda, including Abim,
Agago, Apac, Kitgum, Kaabong, Kotido, Lamwo, Arua, Lira, Pader,
Gulu, Nebbi, Napak, Dokolo, and Yumbe reported suspected cases
of YF (Figure 1). The districts share borders with southern Sudan
and Kenya where outbreaks have been reported in the past.10–13
The northern region is home to a number of game reserves and
parks including Kidepo Valley National Park and Murchison FallsFigure 1. Map showing districts reporting suspect cases, northern Uganda, 2010–
2011.National Park. Northern Uganda has just recovered from a nearly
two-decade civil war that conﬁned more than 90% of the
population to internally displaced people’s (IDP) camps. The YF
outbreak occurred within 2 years after these people had returned
to their original homes.
2.2. Investigation teams
The epidemiology and laboratory team was one of the sub-
committees of the national task force established to respond to the
outbreak. The experts on the team included medical epidemiol-
ogists, physicians, laboratory experts, and social workers drawn
from the Ministry of Health, other sectors in government, and
partner organizations like the World Health Organization (WHO),
Centers for Disease Control and Prevention (CDC), Me´decins Sans
Frontie`res (MSF), and the African Field Epidemiology Network
(AFENET).
2.3. Epidemiology and laboratory activities
2.3.1. Epidemiology
This was a case-series investigation in which the ﬁeld teams
conducted detailed clinical descriptions of all suspected cases. A
working case deﬁnition was developed for the initially unknown
disease, and following the identiﬁcation of YF using the NGS
approach,19 this was modiﬁed (Table 1) to facilitate the
identiﬁcation of additional YF cases at the health facility and
community level. All new suspected YF cases were given
supportive treatment4 at designated treatment centers that
maintained case line-lists with key variables including: identiﬁers,
age, sex, occupation, residence, date of onset of illness, date of
admission to health facility, clinical signs and symptoms, YF
vaccination status, types of specimens collected, date of specimen
collection, laboratory results, case classiﬁcation, and case outcome.
2.3.2. Laboratory
Prior to the conﬁrmation of YF, the types of specimens taken
reﬂected the proposed differential diagnoses (Table 2). Hence from
each suspected case, one to ﬁve blood specimens of 1–3 ml each
were obtained for blood culture, viral serology and genetic testing
by PCR and/or NGS, blood chemistry, full blood counts, and blood
smears. Stool was also obtained in a plain container for microscopy
or placed in Cary–Blair transport medium for stool culture. Liver
autopsy specimens were obtained and preserved in10% formalin to
facilitate YF antigen detection through immunohistochemical
testing. After the conﬁrmation of YF by NGS,19 samples from new
suspected cases were collected for blood chemistry, full blood
counts, and YF testing by PCR and IgM, with conﬁrmation by
plaque reduction neutralization test (PRNT). Because of an ongoing
hepatitis E epidemic in northern Uganda, specimens testing
negative for YF were subsequently tested for hepatitis E virus
and other infections, as elaborated in Table 2.
2.4. Data analysis
A Microsoft Excel data-entry screen incorporating all the
variables on the YF line-list was developed and used to capture all
the information on the cases reported during the outbreak. The
population projections for the affected districts20 were obtained
and used to compute disease attack rates by age, sex, and
geographic location. Attack rate maps were drawn using Epi Map
software.21 Epidemic curves were drawn using the dates of onset
to determine outbreak trends.
All epidemiological and laboratory data were collected as part
of the routine outbreak investigation by national multisector
teams, hence ethical clearance was not obtained.
Table 1
Case deﬁnitions for the epidemiological investigation of the yellow fever outbreak in northern Uganda, 2010–2011
Period Classiﬁcation Deﬁnition
November 8, 2010 to
December 30, 2010
Suspected case Any patient presenting with severe headache with or without fever AND at least three of the following
signs or symptoms:
 Gastrointestinal illness such as vomiting, hematemesis, watery/bloody diarrhea, dark stools (melena),
constipation, foul smelling stools, or
 Dizziness, or
 General weakness, or
 Convulsions, or
 Any unexplained bleeding from another site
December 31, 2010 to
February 9, 2011
Suspected case Any person with acute onset of fever, with either a negative laboratory test (blood slide or RDT) for malaria
or failure to respond to a full course of antimalarials AND any one of the following:
 Jaundice or scleral icterus appearing within 14 days of onset of the ﬁrst symptoms, or
 Unexplained bleeding from either the mouth, nose, gums, skin, eyes, or stomach (gastrointestinal tract)
Probable case Any person meeting the suspected case deﬁnition criteria WITH either:
 An epidemiological link to a conﬁrmed case or the yellow fever outbreak in northern Uganda, or
 Positive post-mortem liver histopathology
Conﬁrmed case Any person meeting the suspected or probable case deﬁnition criteria AND one of the following:
 Detection of yellow fever virus-speciﬁc IgM
 Detection of yellow fever virus-speciﬁc neutralizing antibodies
 Detection of yellow fever virus genome in blood or liver by PCR or NGS
RDT, rapid diagnostic test for malaria; IgM, immunoglobulin M; PCR, polymerase chain reaction; NGS, next generation sequencing.
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3.1. Outbreak investigation and response
Following prolonged outbreak investigations that lasted 40
days, laboratory conﬁrmation of YF was made on December 18,
2010 by the CDC (Atlanta, GA, USA) using a random-primed
pyrosequencing approach.19 Consequently, the Ministry of Health
declared an outbreak of YF in northern Uganda. A national response
plan prioritizing surveillance and laboratory conﬁrmation, case
management, social mobilization and health education, and
reactive vaccination was developed to control the outbreak.
3.2. Index case investigations
In Abim District, the index case was a 41-year-old male from the
village of Wipolo, Aremo Parish, Morulem Sub-County. He
frequented the forest to collect bamboo for sale in the local
market. This forest is located near the village and most homes are
located within a 0.5–1.5 km distance of the forest. His illness
started on October 2, 2010 and was characterized by fever,Table 2
Differential diagnoses investigated during the yellow fever outbreak in northern Ugan
Type of illness Differential diagnoses Laboratory tests und
Bacterial Complicated shigellosis Stool cultures 
Typhoid fever Stool and blood cultu
Escherichia coli (enterohemorrhagic) Stool cultures and Sh
toxin testing
Campylobacter jejuni Stool cultures 
Yersinia enterocolitica Stool cultures 
Clostridium perfringens Stool cultures 
Anthrax Rapid tests, blood cu
Plague Rapid tests, blood cu
Protozoal Entamoeba histolytica Stool microscopy 
Severe malaria Blood slide for malar
Viral Ebola/Marburg, Lassa fever Serology (IgM, IgG), P
Dengue fever Serology (IgM), PRNT
West Nile virus Serology (IgM), PRNT
Yellow fever Serology (IgM), PRNT
Rift valley fever Serology (IgM, IgG), P
Fulminant acute viral hepatitis E Serology (IgM), PCR 
Intoxication Adulterated alcohol Chemical assay (met
CDC, Centers for Disease Control and Prevention; IgM, immunoglobulin M; IgG, immuno
test.headache, epigastric pain, hematemesis, and melena. He was not
treated at any health facility and died 5 days after the onset of
illness. He had not traveled out of his home village or stayed with
any sick persons prior to the onset of illness. A total of ﬁve cases
resulting in two deaths were reported from this family, who shared
the same house. The other four affected house occupants included
a 10-year-old female, a 12-year-old male who died, an eight-year-
old male, and a 16-year-old male. None of the four had traveled to
the forest, but they went down with a similar illness.
In Kitgum District, the index case was a 38-year-old male
hunter from the village of Pudpud, Okuti Parish, Orom Sub-
County. The index case village is located at the edge of a forest, and
hunting gadgets were recovered from the village. His illness
started on November 16, 2010 with complaints of headache, fever,
epigastric pain, epistaxis, red eyes, vomiting dark blood, and
passing feces with blood. He was not taken to any health facility,
but was treated with unspeciﬁed medication and died on
November 22, 2010. The deceased had neither traveled out of
the village nor stayed with sick persons prior to the onset of
illness. Three weeks after he died, the patient’s mother and son fell
sick with similar manifestations. This family had three cases andda, 2010–2011
ertaken Name of Laboratory
Central Public Health Laboratories, Uganda; CDC Atlanta, USA
res Central Public Health Laboratories, Uganda; CDC Atlanta, USA
iga Central Public Health Laboratories, Uganda; CDC Atlanta, USA
Central Public Health Laboratories, Uganda; CDC Atlanta, USA
Central Public Health Laboratories, Uganda; CDC Atlanta, USA
Central Public Health Laboratories, Uganda; CDC Atlanta, USA
ltures Central Public Health Laboratories, Uganda
ltures Uganda Virus Research Institute Plague Laboratory, Arua;
CDC Fort Collins, USA
Central Public Health Laboratories, Uganda
ia parasites Central Public Health Laboratories, Uganda
CR Uganda Virus Research Institute; CDC Atlanta, USA
 CDC Dengue Fever Laboratory, Puerto Rico
 CDC Dengue Fever Laboratory, Puerto Rico
 Uganda Virus Research Institute; CDC Atlanta, USA
CR Uganda Virus Research Institute; CDC Atlanta, USA
Uganda Virus Research Institute
hanol) Uganda Government Analytical Laboratory
globulin G; PCR, polymerase chain reaction; PRNT, plaque reduction neutralization
Figure 2. Suspect yellow fever cases by week of onset, northern Uganda,
2010–2011.
Table 3
Yellow fever suspected case distribution by district, northern Uganda, 2010–2011
District Alive Dead Total District
population 2010
Attack rate
(cases/100 000)
Abim 16 13 29 90 306 32.1
Agago 29 12 41 271 700 15.1
Kitgum 28 7 35 254 800 13.7
Lamwo 11 3 14 132 300 10.6
Pader 3 3 6 210 100 2.9
Total 87 38 125 959 206 13.0
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linked to the index case in Abim.
3.3. Epidemiological description of cases
A total of 273 suspected YF cases including 58 deaths were
reported during the period October 2, 2010 to January 28, 2011
from the 15 districts in northern Uganda. The districts included
Abim, Agago, Apac, Kitgum, Kaabong, Kotido, Lamwo, Arua, Lira,
Pader, Gulu, Nebbi, Napak, Dokolo, and Yumbe.
However, case-based information was available for only 250
(91.6%) suspected cases and 55 (94.8%) deaths that met the initial
(unknown disease) case deﬁnition. Among the cases with case-
based information who met the initial case deﬁnition, 181
suspected YF cases presented with fever and unexplained bleeding
or jaundice and hence met the second YF case deﬁnition; of these
cases, 45 died (case fatality rate (CFR) 24.9%). The subsequent
analysis therefore applies to the 181 cases and 45 deaths that met
the case deﬁnition for YF.
The CFR among males (29.6%; 32/108) was nearly twice that of
females (17.8%; 13/73). The cases meeting the case deﬁnition for
suspected YF were reported from the 10 districts of Abim (29
cases), Agago (41 cases), Apac (one case), Gulu (three cases),
Kaabong (49 cases), Kitgum (35 cases), Lamwo (14 cases), Napak
(two cases), Nebbi (one case), and Pader (six cases).
Among the 181 cases that met the case deﬁnition for suspected
YF, 173 (96%) underwent laboratory testing for YF, and only 13
(7.5%) were laboratory conﬁrmed as YF; these cases came from ﬁve
(50%) of the districts with cases meeting the deﬁnition for
suspected YF. These districts included Agago (two cases), Abim
(seven cases), Kitgum (two cases), Pader (one case), and Lamwo
(one case). The CFR among YF conﬁrmed cases was 53.8% (7/13).
The age of YF suspected cases varied from 3 months to 83 years,
with a mean of 28.2 years, a standard deviation of 17.5 years, and
an interquartile range of 24 years. The age among patients was
almost normally distributed, with a slight skewing towards the
older age groups.
3.4. Clinical presentation
Suspected YF cases presented with fever (100%), any form of
unexplained bleeding (97.8%), headache (71.3%), non-bloody
vomiting (59.7%), hematemesis (52.5%), epistaxis (42.0%), bloody
stools (40.3%), bleeding from at least two sites (13.3%), and
jaundice (11.6%).
The duration between illness onset and recovery varied from 3
to 37 days, with a median of 6 days, a mean of 9 days, and a
standard deviation of 8.9 days. Amongst patients who died, the
duration between onset of illness and death varied from zero to 21
days, with a median of 3 days, a mean of 4 days, and a standard
deviation of 5 days.
The initial case occurred in the 39th epidemiological week of
2010 in Abim District (Figure 2). Epidemiological investigations
were initiated in the 45th epidemiological week of 2010 after
reports of a febrile hemorrhagic illness emerged in Abim District. In
the subsequent weeks there was a gradual increase in cases
reported from the 10 affected districts, reaching a plateau that
stretched from the 46th to the 50th epidemiological week of 2010;
the number of reported cases declined from the 51st epidemiologi-
cal week of 2010 to the 6th epidemiological week of 2011.
Laboratory conﬁrmation was made in the 51st epidemiological
week of 2010, a delay of 6.5 weeks after investigations
commenced. Reactive vaccination was initiated in the 3rd
epidemiological week of 2011.
The overall attack rate (cases per 100 000 population) for YF in
the ﬁve districts where an outbreak was conﬁrmed was 13; thisvaried from 2.9 in Pader to 32.1 in Abim District (Table 3). The risk
of YF transmission was highest in Morulem Sub-County in Abim
District and Paimol Sub-County in Agago District (Figure 3).
In the ﬁve districts where YF was conﬁrmed, the sex-speciﬁc
attack rates showed that males (16.5/100 000 population) were
more affected than females (9.6/10 000 population), with the risk
being at least twice as high in males compared to females in the
districts of Abim, Agago, and Lamwo (Table 4). In addition, the risk
of YF infection increased with age (Figure 4).
By occupation, the cases in the ﬁve districts with conﬁrmed
cases of YF included peasant farmers (36.5%), children (17.3%),
housewives (13.5%), security forces (5.8%), hunters (3%), and
borehole drillers (1%).
3.5. Laboratory ﬁndings
More than half of the patients had a low hemoglobin level
(50.8%); 46.0% had low platelets, 41.3% had lymphocytosis, 38.1%
had neutropenia, and 15.9% had leukopenia. Leukopenia with
lymphocytosis was identiﬁed in 12.7% of cases (Table 5). Liver
transaminases were raised in 30.2% of cases for aspartate
aminotransferase (AST) and 7.9% of cases for alanine aminotrans-
ferase (ALT).
Out of 173 specimens tested, only 13 were conﬁrmed positive
for YF: four cases by PCR, eight cases by IgM and PRNT, and one case
by NGS (454) testing. Molecular sequencing in one of the
conﬁrmed cases revealed 92% homology to the YF virus strain
Couma (Ethiopia), belonging to the East African genotype.19 Two
cases from Agago District were ﬂavivirus-indeterminate following
PRNT testing. Of the samples from Kaabong District, 17.9% (5/28)
were positive for hepatitis E virus-speciﬁc IgM and/or PCR. Seven
patients were positive for plague using a non-validated rapid
antigen test. However, all conﬁrmatory tests for plague (i.e., blood
culture, direct ﬂuorescent antibody test, and phage lysis) were
Figure 3. Distribution of suspect yellow fever cases by sub-county, northern Uganda, 2010–2011.
Table 4
Distribution of yellow fever suspect cases by sex, northern Uganda, 2010–2011
District Male Female Male population 2010 Female population 2010 Attack rate in males
(cases/100 000)
Attack rate in females
(cases/100 000)
Abim 20 9 44 250 46 056 45.2 19.5
Agago 28 13 135 500 136 200 20.7 9.5
Kitgum 19 16 126 500 128 300 15.0 12.5
Lamwo 10 4 67 300 65 000 14.9 6.2
Pader 2 4 105 700 104 400 1.9 3.8
Total 79 46 479 250 479 956 16.5 9.6
Figure 4. Suspect yellow fever case attack rate by age-group in the districts with
conﬁrmed cases, northern Uganda, 2010–2011.
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female from the neighboring district of Gulu had a positive IgM
serological test for Rift Valley fever. Additional testing was
undertaken on samples for the differential diagnoses listed in
Table 2, but test results were negative for those diseases.
4. Discussion
During the period October 2010 to January 2011, Uganda
experienced an outbreak of YF in the north, the largest ever
recorded in the country. The overall attack rate in the ﬁve districts
with conﬁrmed cases was 13 cases per 100 000 population. Prior to
the outbreak in northern Uganda, all of the previous ﬁve YF
outbreaks in Uganda had fewer14 or single cases.15–17 However,
larger outbreaks have been reported in East Africa, with attack
rates (cases per 100 000 persons) of 10 000 in Ethiopia,9 6800 in
Sudan,10 and 27.4 in Kenya.13
In terms of outbreak severity, the CFR of 53.8% reported among
YF conﬁrmed cases in the northern Uganda outbreak is higher than
that of Ethiopia (30%),9 Sudan (10%),10 and Kenya (19%).13 The CFR
Table 5
Summary of interpretations from basic investigations on suspected yellow fever
cases, northern Uganda, 2010–2011
Parameter Frequency
(N = 63)
Percentage
Low hemoglobin 32 50.8
Low platelets 29 46.0
Lymphocytosis 26 41.3
Neutropenia 24 38.1
Raised AST 19 30.2
Leukopenia 10 15.9
Raised creatinine 9 14.3
Lymphopenia 9 14.3
Leukopenia with lymphocytosis 8 12.7
Raised ALT 5 7.9
Raised ALT and AST 5 7.9
Raised total bilirubin 5 7.9
Raised hematocrit 3 4.8
Leukocytosis 3 4.8
Neutrophilia 2 3.2
Raised urea 1 1.6
Raised creatinine and urea 1 1.6
Leukocytosis and neutrophilia 1 1.6
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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timely and deﬁnitive diagnosis. During the YF outbreak in northern
Uganda, laboratory conﬁrmation did not occur until 40 days after
investigations were initiated and hence there was a delay in
initiating the recommended supportive treatment6 and reactive
vaccination. The delay in obtaining laboratory conﬁrmation during
the YF outbreak in northern Uganda is attributable to several
factors. The atypical presentation of cases was one of the reasons
for the delayed conﬁrmation, together with the observation by the
physicians that patients improved on antibiotics and supportive
treatment. The patients identiﬁed during the YF outbreak in
northern Uganda presented with a febrile hemorrhagic illness that
was characterized by fever (100%), any form of unexplained
bleeding (97.8%), and headache (71.3%). Jaundice was a rare
manifestation and was only reported in 11.6% of suspected YF
cases. Hence, given the country’s recent experience with ﬁlovirus
hemorrhagic fever outbreaks,22,23 Ebola and Marburg were the top
diseases on the list of differential diagnoses (Table 2), resulting in
these two diseases being prioritized for laboratory testing. The
ﬁlovirus tests were, however, negative even after repeat testing
was undertaken at both the Uganda Virus Research Institute (UVRI)
and CDC Atlanta. Additionally, once YF was conﬁrmed by NGS
testing,19 specimens had to be shipped out of the country since
testing for YF was not available in Uganda, and this contributed to
delayed conﬁrmation of suspected cases. Due to the weak, case-
based, laboratory-backed surveillance for YF in the country in
recent years, there was no capacity for YF testing in-country when
the outbreak started, hence the need to refer specimens to an
international laboratory.
An investigation into the index clusters in the three districts of
Abim, Agago, and Kitgum revealed that the presentation of cases was
consistent with a febrile hemorrhagic illness with jaundice as a rare
manifestation. However, despite the initial suspicion of a ﬁlovirus
outbreak, there was inconsistent evidence of person-to-person
transmission among close contacts of suspected or conﬁrmed cases.
The epidemic curve for the YF outbreak in northern Uganda showed
a gradual rise in cases before reaching a plateau that lasted for close
to 4 weeks, indicating a continuous common-source epidemic, a
pattern that is seen in vector-borne disease outbreaks like YF due to
delayed initiation of reactive vaccination. The case deﬁnition of YF
that emphasizes jaundice needs to be reviewed in line with the case
presentation in this outbreak to avoid missing YF cases in routine
case-based surveillance.During the outbreak, males were more affected than females
and the risk of infection increased with age. In Africa, humans are
seasonally exposed to YF and hence children who lack naturally
acquired immunity are at high risk of disease.15 Serologic testing
among suspected patients during the YF outbreak in northern
Uganda suggests limited natural or vaccine-induced immunity,
hence adult males who undertake activities inside or close to
forested areas were at higher risk of infection prior to the reactive
vaccination campaign. It therefore seems likely that most human
cases during the outbreak were probably infected by sylvatic
vectors. Additionally, until 2 years prior to the outbreak, the civil
strife in the region had conﬁned families to IDP camps. At the time
the outbreak occurred, most of the families had just returned to
their original homes and hence had to clear forests and/or bush
after being away for close to two decades. In view of the fact that
there were at least two suspected YF cases in each of the case-
series without evidence of travel to forests, this raises the
possibility of urban transmission during the outbreak.
A limitation of this study arises from the fact that not all
suspected YF cases underwent laboratory investigation. The few
suspected cases of YF that were not tested could easily have had
any of the diseases listed as differentials, particularly hepatitis E
virus infection, which has been rampant in the region since 2007.24
Also, 92.8% of suspected YF cases were negative for YF, indicating
that the suspected case deﬁnition was very sensitive; this may be
attributable to the heightened public and clinical concern
regarding the unknown illness and an initially sensitive working
case deﬁnition that was subsequently made speciﬁc for YF, but still
included non-speciﬁc signs like epistaxis, which captured sus-
pected cases who did not have YF. This may be a reﬂection of the
hysteria created in the country by this outbreak. Many cases of
febrile illness with any signs of bleeding were reported as
suspected YF cases. Most of these were not conﬁrmed as YF cases
and were not investigated further. The high CFR in non-YF cases
deserves further investigations.
Following the re-emergence of YF in Uganda, we recommend
that case-based laboratory-backed surveillance for YF is strength-
ened. YF should be considered as a differential in all cases
presenting with a febrile hemorrhagic illness, even in the absence
of jaundice. In addition, the in-country capacity for YF testing
should be re-established. A nationwide risk assessment should be
undertaken to inform the national YF control strategy.
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